O	0	4	High	High	JJ	B-NP
O	4	5	-	-	HYPH	I-NP
O	5	13	mobility	mobility	NN	I-NP
O	14	19	group	group	NN	I-NP
O	20	22	A2	A2	NN	I-NP
O	23	30	protein	protein	NN	I-NP
O	31	40	modulates	modulate	VBZ	B-VP
O	41	46	hTERT	hTERT	NN	B-NP
O	47	60	transcription	transcription	NN	I-NP
O	61	63	to	to	TO	B-VP
O	64	71	promote	promote	VB	I-VP
O	72	85	tumorigenesis	tumorigenesis	NN	B-NP
O	85	86	.	.	.	O

O	88	91	The	The	DT	B-NP
O	92	96	high	high	JJ	I-NP
O	96	97	-	-	HYPH	I-NP
O	97	105	mobility	mobility	NN	I-NP
O	106	111	group	group	NN	I-NP
O	112	114	A2	A2	NN	I-NP
O	115	119	gene	gene	NN	I-NP
O	120	121	(	(	(	O
O	121	126	HMGA2	HMGA2	NN	B-NP
O	126	127	)	)	)	O
O	128	130	is	be	VBZ	B-VP
O	131	134	one	one	CD	B-NP
O	135	137	of	of	IN	B-PP
O	138	141	the	the	DT	B-NP
O	142	146	most	most	RBS	I-NP
O	147	157	frequently	frequently	RB	I-NP
O	158	167	amplified	amplify	VBN	I-NP
O	168	173	genes	gene	NNS	B-NP
O	174	176	in	in	IN	B-PP
O	177	182	human	human	JJ	B-NP
B-Cancer	183	190	cancers	cancer	NNS	I-NP
O	190	191	.	.	.	O

O	192	199	However	However	RB	B-ADVP
O	199	200	,	,	,	O
O	201	210	functions	function	NNS	B-NP
O	211	213	of	of	IN	B-PP
O	214	219	HMGA2	HMGA2	NN	B-NP
O	220	222	in	in	IN	B-PP
O	223	236	tumorigenesis	tumorigenesis	NN	B-NP
O	237	240	are	be	VBP	B-VP
O	241	244	not	not	RB	I-VP
O	245	250	fully	fully	RB	I-VP
O	251	261	understood	understand	VBN	I-VP
O	262	265	due	due	JJ	B-ADJP
O	266	268	to	to	TO	B-PP
O	269	276	limited	limited	JJ	B-NP
O	277	286	knowledge	knowledge	NN	I-NP
O	287	289	of	of	IN	B-PP
O	290	293	its	its	PRP$	B-NP
O	294	301	targets	target	NNS	I-NP
O	302	304	in	in	IN	B-PP
B-Cell	305	310	tumor	tumor	NN	B-NP
I-Cell	311	316	cells	cell	NNS	I-NP
O	316	317	.	.	.	O

O	318	321	Our	Our	PRP$	B-NP
O	322	327	study	study	NN	I-NP
O	328	335	reveals	reveal	VBZ	B-VP
O	336	337	a	a	DT	B-NP
O	338	343	novel	novel	JJ	I-NP
O	344	348	link	link	NN	I-NP
O	349	356	between	between	IN	B-PP
O	357	362	HMGA2	HMGA2	NN	B-NP
O	363	366	and	and	CC	O
O	367	370	the	the	DT	B-NP
O	371	381	regulation	regulation	NN	I-NP
O	382	384	of	of	IN	B-PP
O	385	390	human	human	JJ	B-NP
O	391	401	telomerase	telomerase	NN	I-NP
O	402	409	reverse	reverse	JJ	I-NP
O	410	423	transcriptase	transcriptase	NN	I-NP
O	424	425	(	(	(	O
O	425	430	hTERT	hTERT	NN	B-NP
O	430	431	)	)	)	O
O	431	432	,	,	,	O
O	433	436	the	the	DT	B-NP
O	437	446	catalytic	catalytic	JJ	I-NP
O	447	454	subunit	subunit	NN	I-NP
O	455	457	of	of	IN	B-PP
O	458	468	telomerase	telomerase	NN	B-NP
O	468	469	,	,	,	O
O	470	475	which	which	WDT	B-NP
O	476	482	offers	offer	VBZ	B-VP
O	483	491	critical	critical	JJ	B-NP
O	492	499	insight	insight	NN	I-NP
O	500	504	into	into	IN	B-PP
O	505	508	how	how	WRB	B-ADVP
O	509	514	HMGA2	HMGA2	NN	B-NP
O	515	526	contributes	contribute	VBZ	B-VP
O	527	529	to	to	TO	B-PP
O	530	543	tumorigenesis	tumorigenesis	NN	B-NP
O	543	544	.	.	.	O

O	545	548	The	The	DT	B-NP
O	549	559	expression	expression	NN	I-NP
O	560	562	of	of	IN	B-PP
O	563	568	HMGA2	HMGA2	NN	B-NP
O	569	578	modulates	modulate	VBZ	B-VP
O	579	582	the	the	DT	B-NP
O	583	593	expression	expression	NN	I-NP
O	594	596	of	of	IN	B-PP
O	597	602	hTERT	hTERT	NN	B-NP
O	602	603	,	,	,	O
O	604	613	resulting	result	VBG	B-VP
O	614	616	in	in	IN	B-PP
B-Cell	617	622	cells	cell	NNS	B-NP
O	623	627	with	with	IN	B-PP
O	628	636	enhanced	enhance	VBN	B-NP
O	637	647	telomerase	telomerase	NN	I-NP
O	648	658	activities	activity	NNS	I-NP
O	659	662	and	and	CC	O
O	663	672	increased	increase	VBN	B-NP
B-Cellular_component	673	681	telomere	telomere	NN	I-NP
O	682	688	length	length	NN	I-NP
O	688	689	.	.	.	O

O	690	699	Treatment	Treatment	NN	B-NP
O	700	704	with	with	IN	B-PP
O	705	720	suberoylanilide	suberoylanilide	NN	B-NP
O	721	732	hydroxamide	hydroxamide	NN	I-NP
O	733	734	(	(	(	O
O	734	738	SAHA	SAHA	NN	B-NP
O	738	739	)	)	)	O
O	739	740	,	,	,	O
O	741	742	a	a	DT	B-NP
O	743	750	histone	histone	NN	I-NP
O	751	762	deacetylase	deacetylase	NN	I-NP
O	763	764	(	(	(	O
O	764	768	HDAC	HDAC	NN	B-NP
O	768	769	)	)	)	O
O	770	779	inhibitor	inhibitor	NN	B-NP
O	779	780	,	,	,	O
O	781	787	causes	cause	VBZ	B-VP
O	788	792	dose	dose	NN	B-NP
O	792	793	-	-	HYPH	B-NP
O	793	802	dependent	dependent	JJ	I-NP
O	803	808	hTERT	hTERT	NN	I-NP
O	809	817	reporter	reporter	NN	I-NP
O	818	828	activation	activation	NN	I-NP
O	828	829	,	,	,	O
O	830	839	mimicking	mimic	VBG	B-VP
O	840	845	HMGA2	HMGA2	NN	B-NP
O	846	860	overexpression	overexpression	NN	I-NP
O	860	861	.	.	.	O

O	862	864	By	By	IN	B-PP
O	865	876	interacting	interact	VBG	B-VP
O	877	881	with	with	IN	B-PP
O	882	885	Sp1	Sp1	NN	B-NP
O	885	886	,	,	,	O
O	887	892	HMGA2	HMGA2	NN	B-NP
O	893	903	interferes	interfere	VBZ	B-VP
O	904	908	with	with	IN	B-PP
O	909	912	the	the	DT	B-NP
O	913	924	recruitment	recruitment	NN	I-NP
O	925	927	of	of	IN	B-PP
O	928	933	HDAC2	HDAC2	NN	B-NP
O	934	936	to	to	TO	B-PP
O	937	940	the	the	DT	B-NP
O	941	946	hTERT	hTERT	NN	I-NP
O	947	955	proximal	proximal	JJ	I-NP
O	956	964	promoter	promoter	NN	I-NP
O	964	965	,	,	,	O
O	966	975	enhancing	enhance	VBG	B-VP
O	976	985	localized	localized	JJ	B-NP
O	986	993	histone	histone	NN	I-NP
O	994	996	H3	H3	NN	I-NP
O	996	997	-	-	HYPH	B-NP
O	997	999	K9	K9	NN	I-NP
O	1000	1011	acetylation	acetylation	NN	I-NP
O	1012	1015	and	and	CC	O
O	1016	1023	thereby	thereby	RB	B-VP
O	1024	1035	stimulating	stimulate	VBG	I-VP
O	1036	1041	hTERT	hTERT	NN	B-NP
O	1042	1052	expression	expression	NN	I-NP
O	1053	1056	and	and	CC	O
O	1057	1067	telomerase	telomerase	NN	B-NP
O	1068	1076	activity	activity	NN	I-NP
O	1076	1077	.	.	.	O

O	1078	1086	Moreover	Moreover	RB	B-ADVP
O	1086	1087	,	,	,	O
O	1088	1093	HMGA2	HMGA2	NN	B-NP
O	1094	1103	knockdown	knockdown	VBN	B-VP
O	1104	1106	by	by	IN	B-PP
O	1107	1112	short	short	JJ	B-NP
O	1113	1120	hairpin	hairpin	NN	I-NP
O	1121	1126	HMGA2	HMGA2	NN	I-NP
O	1127	1129	in	in	IN	B-PP
B-Cell	1130	1135	HepG2	HepG2	NN	B-NP
I-Cell	1136	1141	cells	cell	NNS	I-NP
O	1142	1147	leads	lead	VBZ	B-VP
O	1148	1150	to	to	TO	B-PP
O	1151	1162	progressive	progressive	JJ	B-NP
B-Cellular_component	1163	1171	telomere	telomere	NN	I-NP
O	1172	1182	shortening	shortening	NN	I-NP
O	1183	1186	and	and	CC	O
O	1187	1188	a	a	DT	B-NP
O	1189	1199	concurrent	concurrent	JJ	I-NP
O	1200	1208	decrease	decrease	NN	I-NP
O	1209	1211	of	of	IN	B-PP
O	1212	1218	steady	steady	JJ	B-NP
O	1218	1219	-	-	HYPH	I-NP
O	1219	1224	state	state	NN	I-NP
O	1225	1230	hTERT	hTERT	NN	I-NP
O	1231	1235	mRNA	mRNA	NN	I-NP
O	1236	1242	levels	level	NNS	I-NP
O	1242	1243	,	,	,	O
O	1244	1255	attenuating	attenuate	VBG	B-VP
O	1256	1261	their	their	PRP$	B-NP
O	1262	1269	ability	ability	NN	I-NP
O	1270	1272	to	to	TO	B-VP
O	1273	1277	form	form	VB	I-VP
B-Cell	1278	1286	colonies	colony	NNS	B-NP
O	1287	1289	in	in	IN	B-PP
O	1290	1294	soft	soft	JJ	B-NP
O	1295	1299	agar	agar	NN	I-NP
O	1299	1300	.	.	.	O

O	1301	1312	Importantly	Importantly	RB	B-ADVP
O	1312	1313	,	,	,	O
O	1314	1319	HMGA2	HMGA2	NN	B-NP
O	1320	1329	partially	partially	RB	B-ADVP
O	1330	1338	replaces	replace	VBZ	B-VP
O	1339	1342	the	the	DT	B-NP
O	1343	1351	function	function	NN	I-NP
O	1352	1354	of	of	IN	B-PP
O	1355	1360	hTERT	hTERT	NN	B-NP
O	1361	1367	during	during	IN	B-PP
O	1368	1371	the	the	DT	B-NP
O	1372	1383	tumorigenic	tumorigenic	JJ	I-NP
O	1384	1398	transformation	transformation	NN	I-NP
O	1399	1401	of	of	IN	B-PP
O	1402	1408	normal	normal	JJ	B-NP
O	1409	1414	human	human	JJ	I-NP
B-Cell	1415	1426	fibroblasts	fibroblast	NNS	I-NP
O	1426	1427	.	.	.	O

O	1428	1433	These	These	DT	B-NP
O	1434	1442	findings	finding	NNS	I-NP
O	1443	1446	are	be	VBP	B-VP
O	1447	1458	potentially	potentially	RB	B-ADVP
O	1459	1469	clinically	clinically	RB	B-ADJP
O	1470	1478	relevant	relevant	JJ	I-ADJP
O	1478	1479	,	,	,	O
O	1480	1487	because	because	IN	B-SBAR
O	1488	1493	HMGA2	HMGA2	NN	B-NP
O	1494	1504	expression	expression	NN	I-NP
O	1505	1507	is	be	VBZ	B-VP
O	1508	1516	reported	report	VBN	I-VP
O	1517	1519	to	to	TO	I-VP
O	1520	1522	be	be	VB	I-VP
O	1523	1534	upregulated	upregulate	VBN	I-VP
O	1535	1537	in	in	IN	B-PP
O	1538	1539	a	a	DT	B-NP
O	1540	1546	number	number	NN	I-NP
O	1547	1549	of	of	IN	B-PP
O	1550	1555	human	human	JJ	B-NP
B-Cancer	1556	1563	cancers	cancer	NNS	I-NP
O	1564	1566	as	as	IN	B-PP
B-Cellular_component	1567	1575	telomere	telomere	NN	B-NP
O	1576	1587	maintenance	maintenance	NN	I-NP
O	1588	1590	is	be	VBZ	B-VP
O	1591	1600	essential	essential	JJ	B-ADJP
O	1601	1604	for	for	IN	B-PP
O	1605	1618	tumorigenesis	tumorigenesis	NN	B-NP
O	1618	1619	.	.	.	O

